Table 1.
Demographic and Clinical Characteristics of Patients
| Variables | Number |
|---|---|
| Age, median (ranges) (years) | 62 (50–71) |
| Gender | |
| Male | 39 |
| Female | 17 |
| Smoking history | |
| Yes | 13 |
| NO | 43 |
| Clinical stage at diagnosis | |
| III | 8 |
| IV | 48 |
| Genetic alteration status | |
| EGFR-mutated | 6 |
| Wild type | 50 |
| Type of PD-1 blockade | |
| Nivolumab | 39 |
| Pembrolizumab | 17 |
| PD-L1 expression | |
| Low | 32 |
| High | 24 |
| SNX20 expression | |
| Low | 26 |
| High | 30 |
| Response to PD-1 blockade | |
| Responder | 29 |
| Non-responder | 27 |
Abbreviations: EGFR, epidermal growth factor receptor; PD-1, programmed death 1; PD-L1, programmed death ligand 1.